Asfand Yar Cheema/LinkedIn
Sep 4, 2025, 22:00
Asfand Yar Cheema at SOHO 2025: PSM Cohort Study on GLP-1 Agonist Therapy Key Clinical Outcomes for Polycythemia Vera
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Asfand Yar Cheema, Cleveland Clinic
Presents results from a PSM cohort study evaluating the association of GLP-1 agonist therapy and key clinical outcomes in Polycythemia Vera.
GLP-1 agonist therapy is associated with significantly reduced risks of all-cause mortality, myelofibrosis progression, VTE, healthcare utilization, AKI, and ischemic stroke/TIA.
Randomized controlled trials are required to confirm GLP-1 agonist safety and efficacy in PV.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Apr 22, 2026, 17:19Ralf Ludwig: Bridging Population Data and Immunology in Inflammatory Diseases
-
Apr 22, 2026, 17:15Giacomo Rossi: Genetic Study Reveals 10 Genes in Hyperemesis Gravidarum
-
Apr 22, 2026, 17:06Maura Boerio: Quantifying Barriers to Care in Vascular Ehlers-Danlos Syndrome
-
Apr 22, 2026, 17:05Kausik Ray։ Metabolically Healthy Obesity Is Being Re-Evaluated as a High-Risk Condition Needing Closer Attention
-
Apr 22, 2026, 16:58Baba-Jallah Epega: Sickle Cell Resilience Through Patient Voices and Clinical Insight
-
Apr 22, 2026, 16:44Francisco Chacón-Lozsán: Cytokine Storm Is Not Just Inflammation, It Is Organ Failure in Motion
-
Apr 22, 2026, 16:29CBTH 2026 Opens with First Workshop in Germany – European Hematology Association
-
Apr 22, 2026, 16:16Christopher Pittman: Superficial Venous Disease Needs Arterial-Level Follow-Up
-
Apr 22, 2026, 15:47Mohammed Alo: Being Fit Does Not Protect You from High LDL